These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 32347812)

  • 1. Health-Related Effects of Home Nebulization With Glycopyrronium on Difficult-to-Treat Asthma: Post-Hoc Analyses of an Observational Study.
    Talwar D; Bendre S
    Interact J Med Res; 2020 Apr; 9(2):e17863. PubMed ID: 32347812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children.
    Kew KM; Karner C; Mindus SM; Ferrara G
    Cochrane Database Syst Rev; 2013 Dec; 2013(12):CD009019. PubMed ID: 24343671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis.
    Busse WW; Wenzel SE; Casale TB; FitzGerald JM; Rice MS; Daizadeh N; Deniz Y; Patel N; Harel S; Rowe PJ; Graham NMH; O'Riordan T; Pavord ID
    Lancet Respir Med; 2021 Oct; 9(10):1165-1173. PubMed ID: 34181876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
    Wenzel S; Castro M; Corren J; Maspero J; Wang L; Zhang B; Pirozzi G; Sutherland ER; Evans RR; Joish VN; Eckert L; Graham NM; Stahl N; Yancopoulos GD; Louis-Tisserand M; Teper A
    Lancet; 2016 Jul; 388(10039):31-44. PubMed ID: 27130691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.
    Brightling CE; Chanez P; Leigh R; O'Byrne PM; Korn S; She D; May RD; Streicher K; Ranade K; Piper E
    Lancet Respir Med; 2015 Sep; 3(9):692-701. PubMed ID: 26231288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Budesonide-Formoterol for Maintenance and Reliever Therapy Among Patients With Poorly Controlled Asthma: A Systematic Review and Meta-analysis.
    Beasley R; Harrison T; Peterson S; Gustafson P; Hamblin A; Bengtsson T; Fagerås M
    JAMA Netw Open; 2022 Mar; 5(3):e220615. PubMed ID: 35230437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching from salmeterol/fluticasone to formoterol/budesonide combinations improves peripheral airway/alveolar inflammation in asthma.
    Akamatsu T; Shirai T; Kato M; Yasui H; Hashimoto D; Fujisawa T; Tsuchiya T; Inui N; Suda T; Chida K
    Pulm Pharmacol Ther; 2014 Feb; 27(1):52-6. PubMed ID: 23583566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.
    Lee LA; Bailes Z; Barnes N; Boulet LP; Edwards D; Fowler A; Hanania NA; Kerstjens HAM; Kerwin E; Nathan R; Oppenheimer J; Papi A; Pascoe S; Brusselle G; Peachey G; Sule N; Tabberer M; Pavord ID
    Lancet Respir Med; 2021 Jan; 9(1):69-84. PubMed ID: 32918892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study.
    McDowell PJ; Diver S; Yang F; Borg C; Busby J; Brown V; Shrimanker R; Cox C; Brightling CE; Chaudhuri R; Pavord ID; Heaney LG;
    Lancet Respir Med; 2021 Oct; 9(10):1174-1184. PubMed ID: 33971168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Impact of a Digital Dose Counter Pressurized Metered-Dose Inhaler on Uncontrolled Asthma: Cross-Sectional, Observational, Surveillance Study.
    Guleria R; Korukonda K;
    Interact J Med Res; 2019 May; 8(2):e13530. PubMed ID: 31066694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial.
    Pavord ID; Holliday M; Reddel HK; Braithwaite I; Ebmeier S; Hancox RJ; Harrison T; Houghton C; Oldfield K; Papi A; Williams M; Weatherall M; Beasley R;
    Lancet Respir Med; 2020 Jul; 8(7):671-680. PubMed ID: 32171064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formoterol as needed with or without budesonide in patients with intermittent asthma and raised NO levels in exhaled air: A SOMA study.
    Haahtela T; Tamminen K; Malmberg LP; Zetterström O; Karjalainen J; Ylä-Outinen H; Svahn T; Ekström T; Selroos O
    Eur Respir J; 2006 Oct; 28(4):748-55. PubMed ID: 17012630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis.
    Kew KM; Dias S; Cates CJ
    Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD010844. PubMed ID: 24671923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Ferguson GT; FitzGerald JM; Bleecker ER; Laviolette M; Bernstein D; LaForce C; Mansfield L; Barker P; Wu Y; Jison M; Goldman M;
    Lancet Respir Med; 2017 Jul; 5(7):568-576. PubMed ID: 28545978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil counts.
    Muro S; Sugiura H; Darken P; Dorinsky P
    Respir Res; 2021 Jun; 22(1):187. PubMed ID: 34182998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exhaled nitric oxide levels to guide treatment for adults with asthma.
    Petsky HL; Kew KM; Turner C; Chang AB
    Cochrane Database Syst Rev; 2016 Sep; 9(9):CD011440. PubMed ID: 27580628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple Therapy with Mometasone/Indacaterol/Glycopyrronium or Doubling the ICS/LABA Dose in GINA Step 4: IRIDIUM Analyses.
    van Zyl-Smit RN; Kerstjens HAM; Maspero J; Tanase AM; Lawrence D; Mezzi K; D'Andrea P; Chapman KR
    Pulm Ther; 2023 Sep; 9(3):395-409. PubMed ID: 37526856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exhaled nitric oxide levels to guide treatment for children with asthma.
    Petsky HL; Kew KM; Chang AB
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD011439. PubMed ID: 27825189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β
    Bleecker ER; FitzGerald JM; Chanez P; Papi A; Weinstein SF; Barker P; Sproule S; Gilmartin G; Aurivillius M; Werkström V; Goldman M;
    Lancet; 2016 Oct; 388(10056):2115-2127. PubMed ID: 27609408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dupilumab is effective in type 2-high asthma patients receiving high-dose inhaled corticosteroids at baseline.
    Bourdin A; Papi AA; Corren J; Virchow JC; Rice MS; Deniz Y; Djandji M; Rowe P; Pavord ID
    Allergy; 2021 Jan; 76(1):269-280. PubMed ID: 33010038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.